Analysts Expect Clovis Oncology Inc (CLVS) Will Announce Earnings of -$1.24 Per Share
Brokerages expect Clovis Oncology Inc (NASDAQ:CLVS) to announce earnings of ($1.24) per share for the current fiscal quarter, Zacks reports. Four analysts have made estimates for Clovis Oncology’s earnings. The highest EPS estimate is ($0.95) and the lowest is ($1.55). Clovis Oncology reported earnings of ($2.07) per share in the same quarter last year, which would suggest a positive year over year growth rate of 40.1%. The firm is expected to announce its next quarterly earnings report on Monday, August 14th.
According to Zacks, analysts expect that Clovis Oncology will report full-year earnings of ($4.75) per share for the current fiscal year, with EPS estimates ranging from ($5.67) to ($4.10). For the next fiscal year, analysts forecast that the company will report earnings of ($2.95) per share, with EPS estimates ranging from ($4.01) to ($1.48). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that follow Clovis Oncology.
Clovis Oncology (NASDAQ:CLVS) last announced its quarterly earnings results on Wednesday, May 3rd. The biopharmaceutical company reported ($1.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.43) by $0.10. The company had revenue of $7.05 million during the quarter, compared to the consensus estimate of $6.04 million.
A number of equities research analysts have commented on CLVS shares. ValuEngine lowered Clovis Oncology from a “hold” rating to a “sell” rating in a research report on Friday, May 19th. Bank of America Corp reiterated a “buy” rating and issued a $75.00 price target on shares of Clovis Oncology in a research report on Wednesday, May 17th. Chardan Capital lowered Clovis Oncology from a “neutral” rating to a “sell” rating and set a $36.00 price target on the stock. in a research report on Friday, February 3rd. JPMorgan Chase & Co. set a $58.00 price target on Clovis Oncology and gave the company a “hold” rating in a research report on Thursday, February 23rd. Finally, Credit Suisse Group AG upped their price target on Clovis Oncology from $53.00 to $70.00 and gave the company an “outperform” rating in a research report on Thursday, February 23rd. Two analysts have rated the stock with a sell rating, five have issued a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $60.79.
COPYRIGHT VIOLATION WARNING: This article was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://www.americanbankingnews.com/2017/05/25/analysts-expect-clovis-oncology-inc-clvs-will-announce-earnings-of-1-24-per-share.html.
In other news, insider Gillian C. Ivers-Read sold 3,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 15th. The stock was sold at an average price of $66.99, for a total value of $200,970.00. Following the completion of the transaction, the insider now directly owns 209,583 shares of the company’s stock, valued at $14,039,965.17. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Over the last ninety days, insiders sold 9,000 shares of company stock valued at $511,200. 17.40% of the stock is currently owned by corporate insiders.
Several institutional investors have recently added to or reduced their stakes in the stock. Ladenburg Thalmann Financial Services Inc. raised its position in Clovis Oncology by 20.0% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,400 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 400 shares in the last quarter. First Mercantile Trust Co. acquired a new position in Clovis Oncology during the first quarter valued at about $115,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Clovis Oncology by 71.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,819 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 758 shares in the last quarter. PNC Financial Services Group Inc. raised its position in Clovis Oncology by 3.7% in the first quarter. PNC Financial Services Group Inc. now owns 2,800 shares of the biopharmaceutical company’s stock valued at $179,000 after buying an additional 100 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new position in Clovis Oncology during the first quarter valued at about $185,000. 88.48% of the stock is owned by institutional investors.
Shares of Clovis Oncology (NASDAQ:CLVS) traded down 0.586% during mid-day trading on Thursday, reaching $55.155. The company’s stock had a trading volume of 331,987 shares. The firm has a 50 day moving average price of $53.81 and a 200 day moving average price of $52.54. The firm’s market cap is $2.47 billion. Clovis Oncology has a 52-week low of $11.57 and a 52-week high of $74.94.
About Clovis Oncology
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Clovis Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.